ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer
Carcinogenesis · 2024
DOI: 10.1093/carcin/bgae056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carcinogenesis, 2024. Verfasst von Paloma Moreno und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pancreatic Cancer Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Receptors, Adrenergic, alpha-2, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural Program of Center for Cancer Research, The National Cancer Institute, NIH HHS.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) manifests diverse molecular subtypes, including the classical/progenitor and basal-like/squamous subtypes, with the latter known for its aggressiveness. We employed integrative transcriptome and metabolome analyses to identify potential genes contributing to the molecular subtype differentiation and its metabolic features. Our comprehensive analysis revealed that adrenoceptor alpha 2A (ADRA2A) was downregulated in the basal-like/squamous subtype, suggesting its potential role as a candidate suppressor of this subtype. Reduced ADRA2A expression was significantly associated with a high frequency of lymph node metastasis, higher pathological grade, advanced disease stage, and decreased survival among PDAC patients. In vitro experiments demonstrated that ADRA2A transgene expression and ADRA2A agonist inhibited PDAC cell invasion. Additionally, ADRA2A-high condition downregulated the basal-like/squamous gene expression signature, while upregulating the classical/progenitor gene expression signature in our PDAC patient cohort and PDAC cell lines. Metabolome analysis conducted on the PDAC cohort and cell lines revealed that elevated ADRA2A levels were associated with suppressed amino acid and carnitine/acylcarnitine metabolism, which are characteristic metabolic profiles of the classical/progenitor subtype. Collectively, our findings suggest that heightened ADRA2A expression induces transcriptome and metabolome characteristics indicative of classical/progenitor subtype with decreased disease aggressiveness in PDAC patients. These observations introduce ADRA2A as a candidate for diagnostic and therapeutic targeting in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pancreatic Cancer Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
- Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
- Städtisches Klinikum Karlsruhe, Moltkestraße 90, 76133 Karlsruhe, Germany.
- Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.
- Division of General and Oncologic Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, United States.
- Division of Surgical Oncology, Department of Surgery, Thomas Jefferson University, Philadelphia, PA 19107, United States.
ORCID-Profile: Yuuki Ohara, Shouhui Yang, S Perwez Hussain
Förderung
- Intramural Program of Center for Cancer Research
- The National Cancer Institute
- NIH HHS
- National Institutes of Health
Zitieren
APA
Moreno, P., Ohara, Y., Craig, A. J., Liu, H., Yang, S., Dorsey, T. H., Zhang, L., Panigrahi, G., Cawley, H., Azizian, A., Gaedcke, J., Ghadimi, M., Hanna, N., & Hussain, S. P. (2024). ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. Carcinogenesis. https://doi.org/10.1093/carcin/bgae056
Vancouver
Moreno P, Ohara Y, Craig AJ, Liu H, Yang S, Dorsey TH, et al. ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. Carcinogenesis. 2024. doi:10.1093/carcin/bgae056
BibTeX
@article{Moreno2024,
author = {Moreno, Paloma and Ohara, Yuuki and Craig, Amanda J and Liu, Huaitian and Yang, Shouhui and Dorsey, Tiffany H and Zhang, Lin and Panigrahi, Gatikrushna and Cawley, Helen and Azizian, Azadeh and Gaedcke, Jochen and Ghadimi, Michael and Hanna, Nader and Hussain, S Perwez},
title = {ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer},
journal = {Carcinogenesis},
year = {2024},
doi = {10.1093/carcin/bgae056}
}
EUVIMED